as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹863.75
Change
+13.75 (1.62%)
Open
₹855.0
Prev. Close
₹850.0
Day High
₹869.8
Day Low
₹840.55
Volume Analysis
Traded
309,225
Delivered
197,323
Delivery %
63.81%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year EPS growth (25.4%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹904.76 | ₹887.28 | ₹875.51 | ₹858.03 | ₹846.26 | ₹828.78 | ₹817.01 |
| Fibonacci | ₹887.28 | ₹876.11 | ₹869.2 | ₹858.03 | ₹846.86 | ₹839.95 | ₹828.78 |
| Camarilla | ₹871.79 | ₹869.11 | ₹866.43 | ₹858.03 | ₹861.07 | ₹858.39 | ₹855.71 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+3.12%
1 Week
+1.77%
1 Month
+6.18%
3 Months
+4.98%
6 Months
+27.58%
1 Year
-5.07%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹472.47
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.46%
Net margin 8.86% × asset turnover 0.84x × equity multiplier 1.54x
Company Overview
Sector
Healthcare
Market Cap
₹16,708 Cr
P/E (TTM)
22.4
ROE
13.4%
Book Value
₹289.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Alembic Pharma Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Financial Strength (100/100), while Growth (44/100) is the weakest area to weigh before deciding. Strong 3-year EPS growth (25.4%).
TopFund Score — Fundamentals Quality
67/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 35.7%
- −Stock is trading at 2.94 times its book value
- −The company has delivered a poor sales growth of 6.37% over past five years.
- −Tax rate seems low
- −Company has a low return on equity of 12.7% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Alembic Pharmaceuticals will hold one-to-one investor meetings in Mumbai on 23 September 2026.
USFDA issued EIR and closed inspection at Vadodara bioequivalence facility, conducted March 3-7, 2025.
Alembic’s Vadodara bioequivalence facility passed unannounced USFDA inspection from 31 Aug-10 Sep 2026, with no Form 483 observations.
Alembic Pharmaceuticals incorporated wholly owned subsidiary Alembic Pharmaceuticals Global FZCO in Dubai on 24 August 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 |
| Expenses + | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 | 1,818 |
| Operating Profit | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 |
| OPM % | 13.0% | 13.0% | 16.0% | 17.0% | 15.0% | 15.0% | 15.0% | 15.0% | 16.0% | 17.0% | 16.0% | 12.0% | 15.0% |
| Other Income + | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 |
| Interest | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 |
| Depreciation | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 |
| Profit before tax | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 |
| Tax % | 7.0% | -1.0% | 2.0% | 3.0% | 14.0% | 15.0% | 23.0% | 18.0% | 19.0% | 18.0% | 18.0% | -70.0% | 22.0% |
| Net Profit + | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| EPS in Rs | 6 | 7 | 9 | 9 | 7 | 8 | 7 | 8 | 8 | 9 | 7 | 10 | 9 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 | 7,784 |
| Expenses + | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,296 | 5,664 | 6,224 | 6,617 |
| Operating Profit | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 932 | 1,008 | 1,121 | 1,167 |
| OPM % | 20.0% | 32.0% | 20.0% | 21.0% | 22.0% | 27.0% | 27.0% | 16.0% | 12.0% | 15.0% | 15.0% | 15.0% | 15.0% |
| Other Income + | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 28 | 56 | -14 | -1 |
| Interest | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 94 | 98 |
| Depreciation | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 319 | 342 |
| Profit before tax | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 632 | 707 | 694 | 726 |
| Tax % | 21.0% | 23.0% | 23.0% | 22.0% | 21.0% | 20.0% | 19.0% | 17.0% | 4.0% | 3.0% | 18.0% | 3.0% | — |
| Net Profit + | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 616 | 582 | 671 | 690 |
| EPS in Rs | 15 | 38 | 21 | 22 | 31 | 44 | 58 | 27 | 17 | 31 | 30 | 34 | 35 |
| Dividend Payout % | 23.0% | 9.0% | 19.0% | 18.0% | 18.0% | 23.0% | 24.0% | 38.0% | 46.0% | 35.0% | 37.0% | 35.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 | 5,152 | 5,636 |
| Borrowings + | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 513 | 1,258 | 1,430 |
| Other Liabilities + | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,114 | 1,325 | 1,658 |
| Total Liabilities | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
| Fixed Assets + | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 | 2,524 | 3,081 |
| CWIP | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 524 | 837 | 683 |
| Investments | 2 | 87 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 | 141 |
| Other Assets + | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,281 | 4,285 | 4,858 |
| Total Assets | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | 803 | 88 | 783 |
| Cash from Investing Activity + | -256 | -307 | -486 | -884 | -756 | -731 | -840 | -372 | -448 | -321 | -568 | -506 |
| Cash from Financing Activity + | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 | 444 | -164 |
| Net Cash Flow | 3 | 417 | -286 | -69 | 115 | -127 | 26 | -37 | 14 | 45 | -37 | 113 |
| CFO/OP | 60 | 114 | 73 | 70 | 112 | 56 | 115 | 77 | 115 | 88 | 16 | 79 |
| Free Cash Flow | -52 | 647 | 348 | -495 | 49 | -285 | 804 | 128 | 282 | 487 | -466 | 290 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 11.67% | 11.36% | 10.54% | 10.61% | 10.38% | 10.17% | 9.96% | 9.91% | 9.92% | 9.84% | 9.83% | 10.0% |
| Promoters | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.67% | 69.68% | 69.74% | 69.74% | 69.74% | 69.87% |
| FII | 4.51% | 4.52% | 4.46% | 4.32% | 3.94% | 4.17% | 3.94% | 3.96% | 4.04% | 4.23% | 4.26% | 4.17% |
| DII | 14.22% | 14.51% | 15.39% | 15.47% | 16.05% | 16.05% | 16.43% | 16.46% | 16.3% | 16.17% | 16.17% | 15.93% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Alembic Pharma Ltd (this stock) | 16,708 | 22.4 | 2.94 | 13.4% |
| Alivus Life Sciences Ltd | 16,820 | 47.8 | — | — |
| Jubilant Pharmova Ltd | 17,118 | 44.1 | 2.41 | 6.53% |
| Concord Biotech Limited | 16,142 | 58.1 | 7.99 | 12.5% |
| Cohance Lifesciences Ltd | 17,290 | 161.0 | 4.43 | 4.89% |
| Poly Medicure Limited | 17,479 | 54.6 | 5.63 | 9.02% |
| Eris Lifesciences Limited | 17,618 | 26.9 | 4.5 | 18.7% |
Which Mutual Funds Hold Alembic Pharma Ltd?
Frequently Asked Questions about Alembic Pharma Ltd
Alembic Pharma Ltd (APLLTD) closed at ₹863.75 on NSE on 25 September 2026, up 13.75 (1.62%) from the previous close.
Alembic Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol APLLTD.
Alembic Pharma Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 22.4.
Alembic Pharma Ltd has a dividend yield of 1.41%.
Alembic Pharma Ltd's 52-week high is ₹998.0 and its 52-week low is ₹635.0.
Alembic Pharma Ltd has a market capitalisation of ₹16,708 crore.
Alembic Pharma Ltd has a TopFund Quality Score of 67/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Alembic Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.